Cilostazol SPECT Study
- Conditions
- Cerebral inferction
- Registration Number
- JPRN-UMIN000004229
- Lead Sponsor
- akamura Memorial Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Not provided
Patients by whom bypass surgery, CEA, or intravascular treatments are planned Patients with cerebral infarction caused by non-arteriosclerosis. Patients with critical complications such as malignant neoplasm, hepatic cirrhosis, renal failure, respiratory failure. Patients with myocardial infarction for less than six months. Patients with 300 or more mg/dl of fasting plasma glucose levels, or insulin treatment. Patients with 110 or more mmHg of diastolic blood pressure. Patients with artery to artery embolism. Patients with cardiogenic cerebral embolism. Patients with hemorrhage or bleeding tendency (hemophilia, capillary fragility, intracranial hemorrhage, hemorrhage in the digestive tract, hemorrhage in the urinary tract, hemoptysis, and hemorrhage in the vitreous body) Patients with ischemic heart failure Patients with a history of hypersensitivity to salicylic acid formulations or ingredients of cilostazol tablets Patients with aspirin asthma (asthma attacks induced by nonsteroidal antiinflammatory analgesic agents) or a history of aspirin asthma Pregnant, possibly pregnant, or nursing women Patients who are otherwise judged inappropriate for inclusion in the study by the investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The amount of cerebral blood flows at rest and cerebrovascular reserve capacities using the dual-table ARG method
- Secondary Outcome Measures
Name Time Method 1. cardiovascular events (Stroke,MI,PAD etc.) 2.ADL score (m-RS, Barthel index) 3. Existence of the onset of pneumonia